Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Piotr Garnuszek"'
Autor:
Seweryn Krajewski, Lukasz Steczek, Karina Gotowicz, Urszula Karczmarczyk, Joanna Towpik, Ewa Witkowska-Patena, Krzysztof Łyczko, Maciej Mazur, Przemysław Kozanecki, Joanna Włostowska, Juhani Knuuti, Mirosław Dziuk, Piotr Garnuszek, Cezary Kozanecki
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Background Positron emission tomography (PET) is now an established diagnostic method for myocardial perfusion imaging (MPI) in coronary artery disease, which is the main cause of death globally. The available tracers show several limitation
Externí odkaz:
https://doaj.org/article/b265b8146c964dcca69d497194840677
Autor:
Martin Kraihammer, Piotr Garnuszek, Andreas Bauman, Michael Maurin, Manuel Alejandre Lafont, Roland Haubner, Elisabeth von Guggenberg, Michael Gabriel, Clemens Decristoforo
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Background Targeted radionuclide therapy with [177Lu]Lu-PSMA I&T (zadavotide guraxetan) has proven high efficacy and safety in treating patients with advanced prostate cancer worldwide. Several methods to determine the radiochemical purity h
Externí odkaz:
https://doaj.org/article/4c85afc87f8d4dbfa7c2ec18479058c9
Autor:
Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 885 (2023)
Broad availability and cost-effectiveness of 99Mo/99mTc generators worldwide support the use, and thus the development, of novel 99mTc-labelled radiopharmaceuticals. In recent years, preclinical and clinical developments for neuroendocrine neoplasms
Externí odkaz:
https://doaj.org/article/f1622523023c4c7a8174d282234f634f
Autor:
Alice D’Onofrio, Francisco Silva, Lurdes Gano, Paula Raposinho, Célia Fernandes, Arkadiusz Sikora, Monika Wyczółkowska, Renata Mikołajczak, Piotr Garnuszek, António Paulo
Publikováno v:
Pharmaceutics, Vol 14, Iss 12, p 2569 (2022)
Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor radionuclide therapy (PRRT), toxi
Externí odkaz:
https://doaj.org/article/be3a8061859940269765896c9e48ff68
Autor:
Michał Maurin, Monika Wyczółkowska, Agnieszka Sawicka, Arkadiusz Eugeniusz Sikora, Urszula Karczmarczyk, Barbara Janota, Marcin Radzik, Dominik Kłudkiewicz, Justyna Pijarowska-Kruszyna, Antoni Jaroń, Wioletta Wojdowska, Piotr Garnuszek
Publikováno v:
Molecules, Vol 27, Iss 21, p 7216 (2022)
Despite significant advances in nuclear medicine for diagnosing and treating prostate cancer (PCa), research into new ligands with increasingly better biological properties is still ongoing. Prostate-specific membrane antigen (PSMA) ligands show grea
Externí odkaz:
https://doaj.org/article/556af5e2d5bb4c0b94113b833c84ca41
Autor:
Alice D'Onofrio, Francisco Silva, Lurdes Gano, Urszula Karczmarczyk, Renata Mikołajczak, Piotr Garnuszek, António Paulo
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Pre-targeting approaches based on the inverse-electron-demand Diels-Alder (iEDDA) reaction between strained trans-cyclooctenes (TCO) and electron-deficient tetrazines (Tz) have emerged in recent years as valid alternatives to classic targeted strateg
Externí odkaz:
https://doaj.org/article/95098ce148764a879ccdc6ecda980801
Autor:
Piotr F. J. Lipiński, Piotr Garnuszek, Michał Maurin, Raphael Stoll, Nils Metzler-Nolte, Artur Wodyński, Jan Cz. Dobrowolski, Marta K. Dudek, Monika Orzełowska, Renata Mikołajczak
Publikováno v:
EJNMMI Research, Vol 8, Iss 1, Pp 1-10 (2018)
Abstract Background The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus ma
Externí odkaz:
https://doaj.org/article/1c6b973729cd436ea3c17cb4c7ead88c
Autor:
Jarosław B. Ćwikła, Marek Roslan, Iwona Skoneczna, Monika Kempińska-Wróbel, Michał Maurin, Wojciech Rogowski, Barbara Janota, Anna Szarowicz, Piotr Garnuszek
Publikováno v:
Pharmaceuticals, Vol 14, Iss 11, p 1107 (2021)
Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [99mTc]Tc-PSMA-T4 is a new radiopharmaceu
Externí odkaz:
https://doaj.org/article/a0e5ca092f78461a9d09f2c9eaa41c14
Autor:
Anna Lankoff, Malwina Czerwińska, Rafał Walczak, Urszula Karczmarczyk, Kamil Tomczyk, Kamil Brzóska, Giulio Fracasso, Piotr Garnuszek, Renata Mikołajczak, Marcin Kruszewski
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 11, p 5702 (2021)
Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the
Externí odkaz:
https://doaj.org/article/1db067e187e04ceaaf4143326f91b64d
Autor:
Piotr Garnuszek, Urszula Karczmarczyk, Michał Maurin, Arkadiusz Sikora, Jolanta Zaborniak, Justyna Pijarowska-Kruszyna, Antoni Jaroń, Monika Wyczółkowska, Wioletta Wojdowska, Dariusz Pawlak, Piotr F. J. Lipiński, Renata Mikołajczak
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 5, p 2731 (2021)
A new PSMA ligand (PSMA-D4) containing the Glu-CO-Lys pharmacophore connected with a new linker system (L-Trp-4-Amc) and chelator DOTA was developed for radiolabeling with therapeutic radionuclides. Herein we describe the synthesis, radiolabeling, an
Externí odkaz:
https://doaj.org/article/f6b7c2b5e462446b879629d438b04ecd